Compare KraneShares CSI China Internet ETF (KWEB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs TG Therapeutics Inc — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and TG Therapeutics Inc for 16 Days on average.
| KWEB | TGTX | |
|---|---|---|
Market Cap | $4.37B | $8.16B |
Volume | 13,393,361 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $59.06 |
52-Week Low | $23.63 | $26.94 |
Typical Hold Time | 57 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.025, down 1.25% on the day, with a bearish technical outlook showing 18 sell signals versus 0 buy signals across indicators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed positioning with Tidal Investments reducing its stake by 39.1% while HSBC Holdings increased its position by 27.7% in recent quarters.
The outlook remains cautious given China's economic pressures and U.S.-China trade tensions, though potential tariff reductions from the Trump-Xi summit could provide catalysts. Key risks include rising global protectionism against Chinese exports and China's persistent economic rebalancing challenges. The neutral RSI readings suggest potential for consolidation near current levels.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
